<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9057086" created="10/04/2006" creator="Yo Shidahara"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9057086</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="differentiation" sem="Other">Differentiation</term> of <term id="T2" lex="U-937_promonocytic_cell" sem="Cell_cultured">U-937 promonocytic cells</term> by <term id="T3" lex="etoposide" sem="Organic_compound_other">etoposide</term> and <term id="T4" lex="ICRF-193" sem="Organic_compound_other">ICRF-193</term>, two <term id="T5" lex="antitumour_DNA_topoisomerase_II_inhibitor" sem="Organic_compound_other">antitumour <term id="T6" lex="DNA_topoisomerase_II" sem="Protein_molecule">DNA topoisomerase II</term> inhibitors</term> with different mechanisms of action.</sentence>
<event KT="Other" id="E1">
<type class="Cell_differentiation"/>
<theme idref="T2"/>
<clue><clueType>Differentiation</clueType> <linkTheme>of</linkTheme> U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.</clue>
</event>
<event KT="Investigation" id="E2">
<type class="Positive_regulation"/>
<theme idref="E1"/>
<cause idref="T3"/>
<clue>Differentiation of U-937 promonocytic cells <linkCause>by</linkCause> etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.</clue>
<comment>No clueType</comment></event>
<event KT="Investigation" id="E3">
<type class="Positive_regulation"/>
<theme idref="E1"/>
<cause idref="T4"/>
<clue>Differentiation of U-937 promonocytic cells <linkCause>by</linkCause> etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.</clue>
</event>
<event KT="Investigation" id="E4">
<type class="Negative_regulation"/>
<theme idref="T6"/>
<cause idref="T3"/>
<clue>Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II <clueType>inhibitors</clueType> with different mechanisms of action.</clue>
</event>
<event KT="Investigation" id="E5">
<type class="Negative_regulation"/>
<theme idref="T6"/>
<cause idref="T4"/>
<clue>Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II <clueType>inhibitors</clueType> with different mechanisms of action.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">We have compared the action on <term id="T7" lex="U-937_human_promonocytic_leukemia_cell" sem="Cell_cultured">U-937 human promonocytic leukemia cells</term> of two <term id="T8" lex="DNA_topoisomerase_II_inhibitor" sem="Organic_compound_other"><term id="T9" lex="DNA_topoisomerase_II" sem="Protein_molecule">DNA topoisomerase II</term> inhibitors</term>, namely the <term id="T10" lex="epipodophyllotoxin" sem="Organic_compound_other">epipodophyllotoxin</term> <term id="T11" lex="etoposide" sem="Organic_compound_other">etoposide</term> and the <term id="T12" lex="bisdioxopiperazine" sem="Organic_compound_other">bisdioxopiperazine</term> <term id="T13" lex="ICRF-193" sem="Organic_compound_other">ICRF-193</term>.</sentence>
<event KT="Other" id="E6" uncertainty="doubtful">
<type class="Physiological_process"/>
<theme idref="T7"/>
<cause idref="T11"/>
<clue>We have compared the <clueType>action</clueType> <linkTheme>on</linkTheme> U-937 human promonocytic leukemia cells <linkCause>of</linkCause> <corefCause>two DNA topoisomerase II inhibitors</corefCause>, namely the epipodophyllotoxin etoposide and the bisdioxopiperazine ICRF-193.</clue>
</event>
<event KT="Other" id="E7" uncertainty="doubtful">
<type class="Physiological_process"/>
<theme idref="T7"/>
<cause idref="T13"/>
<clue>We have compared the <clueType>action</clueType> <linkTheme>on</linkTheme> U-937 human promonocytic leukemia cells <linkCause>of</linkCause> <corefCause>two DNA topoisomerase II inhibitors</corefCause>, namely the epipodophyllotoxin etoposide and the bisdioxopiperazine ICRF-193.</clue>
</event>
<sentence id="S3">One hour pulse-treatment with 3 microM <term id="T14" lex="etoposide" sem="Organic_compound_other">etoposide</term> caused <term id="T15" lex="topoisomerase" sem="Protein_family_or_group">topoisomerase</term> associated, <term id="T16" lex="primary_DNA_breakage" sem="Other">primary <term id="A1" sem="DNA_molecule">DNA</term> breakage</term>, which was rapidly followed by <term id="T17" lex="apoptosis" sem="Other">apoptosis</term>.</sentence>
<event id="E9">
<type class="DNA_metabolism"/>
<theme idref="A1"/>
<clue>One hour pulse-treatment with 3 microM etoposide caused topoisomerase associated, primary DNA <clueType>breakage</clueType>, which was rapidly followed by apoptosis.</clue>
</event>
<event KT="Analysis" id="E10">
<type class="Positive_regulation"/>
<theme idref="E9"/>
<cause idref="T15"/>
<clue>One hour pulse-treatment with 3 microM etoposide caused topoisomerase <clueType><clueKT>associated</clueKT></clueType>, primary DNA breakage, which was rapidly followed by apoptosis.</clue>
</event>
<event id="E11">
<type class="Positive_regulation"/>
<theme idref="E10"/>
<cause idref="T14"/>
<clue>One hour pulse-<linkCause>treatment with</linkCause> 3 microM etoposide <clueType>caused</clueType> topoisomerase associated, primary DNA breakage, which was rapidly followed by apoptosis.</clue>
</event>
<event Manner="High" id="E12">
<type class="Positive_regulation"/>
<theme idref="T17"/>
<cause idref="E11"/>
<clue>One hour pulse-treatment with 3 microM etoposide caused topoisomerase associated, primary DNA breakage, which was <clueManner>rapidly</clueManner> <clueType>followed</clueType> <linkTheme>by</linkTheme> apoptosis.</clue>
</event>
<sentence id="S4">By contrast, these effects were not observed upon pulse-treatment with 6 microM <term id="T18" lex="ICRF-193" sem="Organic_compound_other">ICRF-193</term>.</sentence>
<event Polarity="Negative" assertion="non-exist" id="E13">
<type class="Positive_regulation"/>
<theme idref="E10"/>
<cause idref="T18"/>
<clue>By contrast, <corefTheme>these effects</corefTheme> were <cluePolarity>not</cluePolarity> <clueType><clueKT>observed</clueKT></clueType> <linkCause>upon pulse-treatment with</linkCause> 6 microM ICRF-193.</clue>
</event>
<sentence id="S5">However, continuous treatments with <term id="T19" lex="subcytotoxic_concentration" sem="Other">subcytotoxic concentrations</term> of <term id="T20" lex="etoposide" sem="Organic_compound_other">etoposide</term> (0.15 microM) and <term id="T21" lex="ICRF-193" sem="Organic_compound_other">ICRF-193</term> (0.3 microM) produced several similar effects, namely <term id="T22" lex="decreased_cell_proliferation" sem="Other">decreased <term id="A2" sem="Cell_natural">cell</term> proliferation</term>, accumulation of <term id="A3" sem="Cell_natural">cells at G2</term>, increase in <term id="A4" sem="Other">cell mass</term>, and induction of <term id="A5" sem="Other">differentiation</term>.</sentence>
<event id="E49">
<type class="Cellular_physiological_process"/>
<theme idref="A2"/>
<clue>However, continuous treatments with subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) produced several similar effects, namely decreased cell <clueType>proliferation</clueType>, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
<comment>TPS A3</comment></event>
<event id="E16">
<type class="Negative_regulation"/>
<theme idref="E49"/>
<clue>However, continuous treatments with subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) produced several similar effects, namely <clueType>decreased</clueType> cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E17">
<type class="Cellular_physiological_process"/>
<theme idref="A3"/>
<clue>However, continuous treatments with subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) produced several similar effects, namely decreased cell proliferation, <clueType>accumulation</clueType> of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E18">
<type class="Cellular_physiological_process"/>
<theme idref="A4"/>
<clue>However, continuous treatments with subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) produced several similar effects, namely decreased cell proliferation, accumulation of cells at G2, <clueType>increase</clueType> <linkTheme>in</linkTheme> cell mass, and induction of differentiation.</clue>
</event>
<event id="E19">
<type class="Positive_regulation"/>
<theme idref="A5"/>
<clue>However, continuous treatments with subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) produced several similar effects, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and <clueType>induction</clueType> <linkTheme>of</linkTheme> differentiation.</clue>
</event>
<event id="E20">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T20"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E21">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T21"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E22">
<type class="Positive_regulation"/>
<theme idref="E17"/>
<cause idref="T20"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E23">
<type class="Positive_regulation"/>
<theme idref="E17"/>
<cause idref="T21"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E24">
<type class="Positive_regulation"/>
<theme idref="E18"/>
<cause idref="T20"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E25">
<type class="Positive_regulation"/>
<theme idref="E18"/>
<cause idref="T21"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E26">
<type class="Positive_regulation"/>
<theme idref="E19"/>
<cause idref="T20"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<event id="E27">
<type class="Positive_regulation"/>
<theme idref="E19"/>
<cause idref="T21"/>
<clue>However, continuous <linkCause>treatments with</linkCause> subcytotoxic concentrations of etoposide (0.15 microM) and ICRF-193 (0.3 microM) <clueType>produced</clueType> <corefTheme>several similar effects</corefTheme>, namely decreased cell proliferation, accumulation of cells at G2, increase in cell mass, and induction of differentiation.</clue>
</event>
<sentence id="S6">Under these conditions, <term id="T23" lex="etoposide" sem="Organic_compound_other">etoposide</term> produced a <term id="T24" lex="biphasic_activation" sem="Other">biphasic activation</term> of <term id="T25" lex="protein_kinase_C" sem="Protein_molecule">protein kinase C</term>, which consisted in an early transient activation (from hours 1 to 6) of the <term id="T26" lex="membrane-bound_enzyme" sem="Protein_family_or_group">membrane-bound enzyme</term> followed by a later activation (hour 48) of the total, <cons id="T27" lex="(AND membrane-bound_enzyme cytosolic_enzyme)" sem="(AND Protein_family_or_group Protein_family_or_group)"><frag id="F1">membrane-bound</frag> and <frag id="F2">cytosolic</frag> <frag id="F3">enzyme</frag></cons>.</sentence>
<event id="E28">
<type class="Positive_regulation"/>
<theme idref="T25"/>
<cause idref="T23"/>
<clue>Under these conditions, etoposide <clueType>produced</clueType> a biphasic <clueType>activation</clueType> <linkTheme>of</linkTheme> protein kinase C, which consisted in an early transient activation (from hours 1 to 6) of the membrane-bound enzyme followed by a later activation (hour 48) of the total, membrane-bound and cytosolic enzyme.</clue>
</event>
<event id="E29">
<type class="Positive_regulation"/>
<theme idref="T25"/>
<cause idref="T23"/>
<clue>Under these conditions, etoposide produced a biphasic activation of protein kinase C, which consisted in an early transient <clueType>activation</clueType> (<clueTime>from hours 1 to 6</clueTime>) <linkTheme>of</linkTheme> the membrane-bound <corefTheme>enzyme</corefTheme> followed by a later activation (hour 48) of the total, membrane-bound and cytosolic enzyme.</clue>
<comment>No corefCause</comment></event>
<event id="E30">
<type class="Positive_regulation"/>
<theme idref="T25"/>
<cause idref="T23"/>
<clue>Under these conditions, etoposide produced a biphasic activation of protein kinase C, which consisted in an early transient activation (from hours 1 to 6) of the membrane-bound enzyme followed by a later <clueType>activation</clueType> (<clueTime>hour 48</clueTime>) <linkTheme>of</linkTheme> the total, membrane-bound and cytosolic <corefTheme>enzyme</corefTheme>.</clue>
<comment>No corefCause</comment></event>
<sentence id="S7">By contrast, <term id="T28" lex="ICRF-193" sem="Organic_compound_other">ICRF-193</term> only provoked a late activation (from hours 72 to 96) of the total enzyme.</sentence>
<event id="E31">
<type class="Positive_regulation"/>
<theme idref="T27"/>
<cause idref="T28"/>
<clue>By contrast, ICRF-193 only <clueType>provoked</clueType> a late <clueType>activation</clueType> (from hours 72 to 96) <linkTheme>of</linkTheme> <corefTheme>the total enzyme</corefTheme>.</clue>
</event>
<sentence id="S8">When used at differentiation-inducing concentrations, both <term id="T29" lex="topoisomerase" sem="Protein_family_or_group">topoisomerase</term> inhibitors caused a great stimulation of <term id="T30" lex="AP-1_binding_activity" sem="Other"><term id="T31" lex="AP-1" sem="Protein_molecule">AP-1</term> binding activity</term>, with maximum value at hour 12 in <term id="T32" lex="etoposide" sem="Organic_compound_other">etoposide</term>-treated cells and at hour 48 in <term id="T33" lex="ICRF-193-treated_cell" sem="Cell_natural"><term id="T34" lex="ICRF-193" sem="Organic_compound_other">ICRF-193</term>-treated cells</term>.</sentence>
<event id="E32">
<type class="Binding"/>
<theme idref="T31"/>
<clue>When used at differentiation-inducing concentrations, both topoisomerase inhibitors caused a great stimulation of AP-1 <clueType>binding</clueType> activity, with maximum value at hour 12 in etoposide-treated cells and at hour 48 in ICRF-193-treated cells.</clue>
</event>
<event Manner="High" id="E33">
<type class="Positive_regulation"/>
<theme idref="E32"/>
<cause idref="T32"/>
<clue>When used at differentiation-inducing concentrations, <corefCause>both topoisomerase inhibitors</corefCause> <clueType>caused</clueType> a <clueManner>great</clueManner> <clueType>stimulation</clueType> <linkTheme>of</linkTheme> AP-1 binding activity, <clueManner>with maximum value</clueManner> <clueTime>at hour 12</clueTime> <clueLoc>in etoposide-treated cells</clueLoc> and at hour 48 in ICRF-193-treated cells.</clue>
</event>
<event Manner="High" id="E34">
<type class="Positive_regulation"/>
<theme idref="E32"/>
<cause idref="T34"/>
<clue>When used at differentiation-inducing concentrations, <corefCause>both topoisomerase inhibitors</corefCause> <clueType>caused</clueType> a <clueManner>great</clueManner> <clueType>stimulation</clueType> <linkTheme>of</linkTheme> AP-1 binding activity, <clueManner>with maximum value</clueManner> at hour 12 in etoposide-treated cells and <clueTime>at hour 48</clueTime> <clueLoc>in ICRF-193-treated cells</clueLoc>.</clue>
</event>
<sentence id="S9">By contrast, the binding activity of the <term id="T35" lex="NF-kappa(B)" sem="Protein_complex">NF-kappa(B)</term> and <term id="T36" lex="EGR-1" sem="Protein_molecule">EGR-1</term> <term id="T37" lex="transcription_factor" sem="Protein_family_or_group">transcription factors</term> was little affected.</sentence>
<event id="E35">
<type class="Binding"/>
<theme idref="T35"/>
<clue>By contrast, the <clueType>binding</clueType> activity <linkTheme>of</linkTheme> the NF-kappa(B) and EGR-1 transcription factors was little affected.</clue>
</event>
<event id="E36">
<type class="Binding"/>
<theme idref="T36"/>
<clue>By contrast, the <clueType>binding</clueType> activity <linkTheme>of</linkTheme> the NF-kappa(B) and EGR-1 transcription factors was little affected.</clue>
</event>
<event Manner="Low" assertion="non-exist" id="E37">
<type class="Positive_regulation"/>
<theme idref="E35"/>
<cause idref="T32"/>
<clue>By contrast, the binding activity of the NF-kappa(B) and EGR-1 transcription factors was <clueManner>little</clueManner> <clueType>affected</clueType>.</clue>
<comment>No corefCause</comment></event>
<event Manner="Low" assertion="non-exist" id="E38">
<type class="Positive_regulation"/>
<theme idref="E36"/>
<cause idref="T32"/>
<clue>By contrast, the binding activity of the NF-kappa(B) and EGR-1 transcription factors was <clueManner>little</clueManner> <clueType>affected</clueType>.</clue>
<comment>No corefCause</comment></event>
<event Manner="Low" assertion="non-exist" id="E39">
<type class="Positive_regulation"/>
<theme idref="E35"/>
<cause idref="T34"/>
<clue>By contrast, the binding activity of the NF-kappa(B) and EGR-1 transcription factors was <clueManner>little</clueManner> <clueType>affected</clueType>.</clue>
<comment>No corefCause</comment></event>
<event Manner="Low" assertion="non-exist" id="E40">
<type class="Positive_regulation"/>
<theme idref="E36"/>
<cause idref="T34"/>
<clue>By contrast, the binding activity of the NF-kappa(B) and EGR-1 transcription factors was <clueManner>little</clueManner> <clueType>affected</clueType>.</clue>
<comment>No corefCause</comment></event>
<sentence id="S10">It is concluded that <term id="T38" lex="topoisomerase_II_inhibitor" sem="Organic_compound_other">topoisomerase II inhibitors</term> may induce the differentiation of <term id="A6" sem="Cell_natural">promonocytic cells</term>, independently of their capacity to cause <term id="T39" lex="DNA_strand_break" sem="Other"><term id="A7" sem="DNA_molecule">DNA strand</term> breaks</term>.</sentence>
<event KT="Other" id="E41">
<type class="Cell_differentiation"/>
<theme idref="A6"/>
<clue>It is concluded that topoisomerase II inhibitors may induce the <clueType>differentiation</clueType> <linkTheme>of</linkTheme> promonocytic cells, independently of their capacity to cause DNA strand breaks.</clue>
</event>
<event KT="Other" id="E42">
<type class="DNA_metabolism"/>
<theme idref="A7"/>
<clue>It is concluded that topoisomerase II inhibitors may induce the differentiation of promonocytic cells, independently of their capacity to cause DNA strand <clueType>breaks</clueType>.</clue>
</event>
<event CL="L1" KT="Analysis" id="E43">
<type class="Positive_regulation"/>
<theme idref="E41"/>
<cause idref="T38"/>
<clue>It is <clueKT>concluded</clueKT> that topoisomerase II inhibitors <clueCL>may</clueCL> <clueType>induce</clueType> the differentiation of promonocytic cells, independently of their capacity to cause DNA strand breaks.</clue>
</event>
<event KT="Other" id="E44">
<type class="Positive_regulation"/>
<theme idref="E42"/>
<cause idref="T38"/>
<clue>It is concluded that topoisomerase II inhibitors may induce the differentiation of promonocytic cells, independently of <corefCause>their capacity</corefCause> to <clueType>cause</clueType> DNA strand breaks.</clue>
</event>
<event KT="Other" Polarity="Negative" assertion="non-exist" id="E45">
<type class="Correlation"/>
<theme idref="E43"/>
<theme idref="E44"/>
<clue>It is concluded that topoisomerase II inhibitors may induce the differentiation of promonocytic cells, <clueType><cluePolarity>independently</cluePolarity></clueType> <linkTheme>of</linkTheme> their capacity to cause DNA strand breaks.</clue>
</event>
<sentence id="S11">However, there are other effects, such as the early activation of <term id="T40" lex="protein_kinase_C" sem="Protein_molecule">protein kinase C</term>, which are probably derived from the production of primary <term id="A8" sem="DNA_molecule">DNA</term> breakage by some <term id="T41" lex="anti-topoisomerase_drug" sem="Organic_compound_other">anti-<term id="T42" lex="topoisomerase" sem="Protein_family_or_group">topoisomerase</term> drugs</term>.</sentence>
<event KT="Other" id="E46">
<type class="Positive_regulation"/>
<theme idref="T40"/>
<clue>However, there are other effects, such as the early <clueType>activation</clueType> <linkTheme>of</linkTheme> protein kinase C, which are probably derived from the production of primary DNA breakage by some anti-topoisomerase drugs.</clue>
</event>
<event KT="Other" id="E47">
<type class="DNA_metabolism"/>
<theme idref="A8"/>
<cause idref="T41"/>
<clue>However, there are other effects, such as the early activation of protein kinase C, which are probably derived from the production of primary DNA <clueType>breakage</clueType> <linkCause>by</linkCause> some anti-topoisomerase drugs.</clue>
</event>
<event CL="L2" KT="Analysis" id="E48" uncertainty="probable">
<type class="Positive_regulation"/>
<theme idref="E46"/>
<cause idref="E47"/>
<clue>However, there are other effects, such as the early activation of protein kinase C, which are <clueKT><clueCL>probably</clueCL></clueKT> <clueType>derived</clueType> <linkCause>from</linkCause> the production of primary DNA breakage by some anti-topoisomerase drugs.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
